ArticleCureus2025
Paclitaxel-Induced Hypertriglyceridemia Complicated by Acute Pancreatitis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel, a widely used chemotherapy agent, has been associated with various adverse effects, including hypertriglyceridemia and, rarely, acute pancreatitis. The potential for paclitaxel to trigger lipid metabolism disturbances necessitates close monitoring of lipid profiles in patients undergoing treatment. We report the case of a 48-year-old woman with a history of breast cancer who developed acute pancreatitis following paclitaxel chemotherapy. She presented with abdominal pain radiating to the back, nausea, and vomiting one week after her fourth cycle of paclitaxel. Imaging confirmed acute pancreatitis, and laboratory studies revealed significantly elevated serum triglyceride and lipase levels. Paclitaxel was discontinued, and the patient was managed with lipid-lowering therapy, analgesics, and intravenous hydration, leading to clinical improvement and normalization of triglyceride and lipase levels. She was subsequently referred back to the oncology team for further guidance on her breast cancer therapy. Given her paclitaxel-based regimen, chemotherapy-induced hypertriglyceridemia complicated by pancreatitis was strongly suspected. This case highlights the importance of early recognition and monitoring of lipid levels in patients receiving paclitaxel chemotherapy, as prompt intervention can prevent severe complications. Further research is warranted to elucidate the mechanisms and risk factors for this rare but life-threatening adverse effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.